Nikola Vasev

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study

Sandra M. Swain, David Miles, Sung‐Bae Kim et al. · The Lancet Oncology · 2020 · 898 citations

Medicine, Oncology, Pharmacology +14

Trilaciclib plus chemotherapy versus chemotherapy alone in patients with metastatic triple-negative breast cancer: a multicentre, randomised, open-label, phase 2 trial

Antoinette R. Tan, Gail S. Wright, Anu Thummala et al. · The Lancet Oncology · 2019 · 115 citations

Medicine, Oncology, Pharmacology +11

Trilaciclib Prior to Chemotherapy in Patients with Metastatic Triple-Negative Breast Cancer: Final Efficacy and Subgroup Analysis from a Randomized Phase II Study

Antoinette R. Tan, Gail S. Wright, Anu Thummala et al. · Clinical Cancer Research · 2021 · 42 citations · Full text

Medicine, Oncology, Pharmacology +17